The emergence of PET in the diagnostic work-up of prostate cancer, specifically PSMA-PET, shows promise in the detection of recurrence in patients where conventional imaging (whole body bone scan, CT) may be negative. This evidence concerns the gene FOLH1 and Familial prostate cancer.